NASDAQ:INGN Inogen (INGN) Stock Price, News & Analysis → The 2024 Gold Rush: Unleashing Market Potential (From Priority Gold) (Ad) Free INGN Stock Alerts $8.69 +0.45 (+5.46%) (As of 05/9/2024 ET) Add Compare Share Share Today's Range$8.03▼$8.8750-Day Range$6.30▼$8.6952-Week Range$4.13▼$11.98Volume657,426 shsAverage Volume531,525 shsMarket Capitalization$204.62 millionP/E RatioN/ADividend YieldN/APrice Target$7.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Inogen alerts: Email Address Inogen MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside19.4% Downside$7.00 Price TargetShort InterestBearish7.73% of Shares Sold ShortDividend StrengthN/ASustainability-1.12Upright™ Environmental ScoreNews Sentiment0.51Based on 16 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.56) to ($1.96) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.38 out of 5 starsMedical Sector481st out of 915 stocksSurgical Appliances & Supplies Industry13th out of 18 stocks 1.0 Analyst's Opinion Consensus RatingInogen has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 2 hold ratings, and 1 sell rating.Amount of Analyst CoverageInogen has only been the subject of 3 research reports in the past 90 days.Read more about Inogen's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted7.73% of the outstanding shares of Inogen have been sold short.Short Interest Ratio / Days to CoverInogen has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Inogen has recently increased by 7.69%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldInogen does not currently pay a dividend.Dividend GrowthInogen does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreInogen has received a 51.98% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Medical ventilators" product. See details.Environmental SustainabilityThe Environmental Impact score for Inogen is -1.12. Previous Next 2.5 News and Social Media Coverage News SentimentInogen has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Inogen this week, compared to 2 articles on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Inogen insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.99% of the stock of Inogen is held by insiders.Percentage Held by Institutions89.94% of the stock of Inogen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Inogen's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Inogen are expected to grow in the coming year, from ($2.56) to ($1.96) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Inogen is -1.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Inogen is -1.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInogen has a P/B Ratio of 0.99. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Inogen's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About Inogen Stock (NASDAQ:INGN)Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Simeox airway clearance; batteries; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.Read More INGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INGN Stock News HeadlinesMay 9, 2024 | markets.businessinsider.comStifel Nicolaus Reaffirms Their Hold Rating on Inogen (INGN)May 9, 2024 | finance.yahoo.comEarnings Update: Here's Why Analysts Just Lifted Their Inogen, Inc. (NASDAQ:INGN) Price Target To US$7.00May 9, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.May 8, 2024 | finance.yahoo.comInogen, Inc. (NASDAQ:INGN) Q1 2024 Earnings Call TranscriptMay 8, 2024 | finance.yahoo.comQ1 2024 Inogen Inc Earnings CallMay 8, 2024 | finance.yahoo.comInogen Inc (INGN) Q1 2024 Earnings Call Transcript Highlights: Navigating Market Dynamics with ...May 7, 2024 | investorplace.comINGN Stock Earnings: Inogen Beats EPS, Beats Revenue for Q1 2024May 7, 2024 | washingtonpost.comInogen: Q1 Earnings SnapshotMay 9, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.May 7, 2024 | finance.yahoo.comInogen Inc (INGN) Q1 2024 Earnings: Navigating Challenges with a Focus on GrowthMay 7, 2024 | businesswire.comInogen Announces First Quarter 2024 Financial ResultsMay 1, 2024 | americanbankingnews.comShort Interest in Inogen, Inc. (NASDAQ:INGN) Expands By 7.7%April 30, 2024 | americanbankingnews.comInogen (INGN) Set to Announce Quarterly Earnings on TuesdayApril 13, 2024 | seekingalpha.comInogen: New Management And A Major Competitor Exit Offer Some New OpportunitiesApril 10, 2024 | businesswire.comInogen to Report First Quarter 2024 Financial Results on May 7, 2024April 9, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Inogen (INGN) and Galectin Therapeutics (GALT)March 25, 2024 | businesswire.comInogen To Present at 23rd Annual Needham Virtual Healthcare ConferenceMarch 18, 2024 | ca.finance.yahoo.comINGN Apr 2024 10.000 callMarch 17, 2024 | finance.yahoo.comINGN Apr 2024 5.000 putMarch 17, 2024 | finance.yahoo.comINGN Apr 2024 15.000 callMarch 16, 2024 | finance.yahoo.comINGN Apr 2024 12.500 callMarch 16, 2024 | finance.yahoo.comINGN Apr 2024 7.500 putMarch 13, 2024 | finanznachrichten.deInogen Alliance: Preparing for 4 New EU Environmental Regulations in 2024March 7, 2024 | businesswire.comInogen, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)March 1, 2024 | finance.yahoo.comInogen Full Year 2023 Earnings: EPS Misses ExpectationsFebruary 29, 2024 | finance.yahoo.comInogen, Inc. (NASDAQ:INGN) Q4 2023 Earnings Call TranscriptFebruary 29, 2024 | barrons.comInogen Inc.See More Headlines Receive INGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Inogen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today5/09/2024Next Earnings (Estimated)8/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical appliances & supplies Sub-IndustryN/A Current SymbolNASDAQ:INGN CUSIPN/A CIK1294133 Webwww.inogen.com Phone(805) 562-0500FaxN/AEmployees834Year Founded2001Price Target and Rating Average Stock Price Target$7.00 High Stock Price Target$7.00 Low Stock Price Target$7.00 Potential Upside/Downside-19.4%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($4.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-102,450,000.00 Net Margins-32.46% Pretax Margin-32.42% Return on Equity-38.98% Return on Assets-27.03% Debt Debt-to-Equity RatioN/A Current Ratio2.86 Quick Ratio2.55 Sales & Book Value Annual Sales$315.66 million Price / Sales0.65 Cash FlowN/A Price / Cash FlowN/A Book Value$8.79 per share Price / Book0.99Miscellaneous Outstanding Shares23,547,000Free Float23,314,000Market Cap$204.62 million OptionableOptionable Beta1.10 Social Links 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Kevin R. M. Smith (Age 53)President, CEO & Director Comp: $1.62MMr. Jason Somer (Age 56)Executive VP, General Counsel & Corporate Secretary Comp: $401.03kDr. Stanislav Glezer M.D. (Age 51)MBA, Executive VP of R&D and Chief Medical Officer Comp: $575.36kMr. Michael J. Bourque (Age 61)Executive VP, CFO & Treasurer Mr. Philip CorrinSenior Vice President of Operations & Supply ChainMs. Jennifer Yi BoyerExecutive VP & Chief Human Resources OfficerMr. Vijay PaliwalSenior Vice President of Enterprise EnablementMr. Grgoire Ramade (Age 54)Executive VP & Chief Commercial Officer More ExecutivesKey CompetitorsCollPlant BiotechnologiesNASDAQ:CLGNEnvoy MedicalNASDAQ:COCHSanara MedTechNASDAQ:SMTIMilestone ScientificNYSE:MLSSVicarious SurgicalNYSE:RBOTView All CompetitorsInstitutional OwnershipBlair William & Co. ILSold 3,777 shares on 5/9/2024Ownership: 0.152%Inspire Advisors LLCBought 31,596 shares on 5/8/2024Ownership: 0.134%Stokes Family Office LLCBought 43,485 shares on 5/7/2024Ownership: 0.185%Oppenheimer Asset Management Inc.Bought 15,016 shares on 5/7/2024Ownership: 0.064%Susquehanna Fundamental Investments LLCBought 10,032 shares on 5/7/2024Ownership: 0.043%View All Institutional Transactions INGN Stock Analysis - Frequently Asked Questions Should I buy or sell Inogen stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Inogen in the last year. There are currently 1 sell rating, 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" INGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INGN, but not buy additional shares or sell existing shares. View INGN analyst ratings or view top-rated stocks. What is Inogen's stock price target for 2024? 4 brokers have issued 12-month price targets for Inogen's shares. Their INGN share price targets range from $7.00 to $7.00. On average, they anticipate the company's share price to reach $7.00 in the next twelve months. This suggests that the stock has a possible downside of 19.4%. View analysts price targets for INGN or view top-rated stocks among Wall Street analysts. How have INGN shares performed in 2024? Inogen's stock was trading at $5.49 at the start of the year. Since then, INGN stock has increased by 58.3% and is now trading at $8.69. View the best growth stocks for 2024 here. Are investors shorting Inogen? Inogen saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 1,820,000 shares, an increase of 7.7% from the March 31st total of 1,690,000 shares. Based on an average daily trading volume, of 536,700 shares, the days-to-cover ratio is currently 3.4 days. View Inogen's Short Interest. When is Inogen's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 5th 2024. View our INGN earnings forecast. How were Inogen's earnings last quarter? Inogen, Inc. (NASDAQ:INGN) released its quarterly earnings data on Tuesday, May, 7th. The medical technology company reported ($0.62) earnings per share for the quarter, topping analysts' consensus estimates of ($0.76) by $0.14. The medical technology company had revenue of $78.03 million for the quarter, compared to analyst estimates of $73.67 million. Inogen had a negative net margin of 32.46% and a negative trailing twelve-month return on equity of 38.98%. The firm's revenue was up 8.1% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.63) earnings per share. What guidance has Inogen issued on next quarter's earnings? Inogen updated its second quarter 2024 earnings guidance on Wednesday, May, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $81.0 million-$84.0 million, compared to the consensus revenue estimate of $84.2 million. What is Scott Wilkinson's approval rating as Inogen's CEO? 70 employees have rated Inogen Chief Executive Officer Scott Wilkinson on Glassdoor.com. Scott Wilkinson has an approval rating of 46% among the company's employees. This puts Scott Wilkinson in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Inogen own? Based on aggregate information from My MarketBeat watchlists, some companies that other Inogen investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Incyte (INCY), (MDVN) (MDVN), NVIDIA (NVDA), Alibaba Group (BABA), Advanced Micro Devices (AMD), First Solar (FSLR), Intel (INTC) and Netflix (NFLX). Who are Inogen's major shareholders? Inogen's stock is owned by a number of retail and institutional investors. Top institutional investors include BNP Paribas Financial Markets (0.19%), Stokes Family Office LLC (0.18%), Mission Wealth Management LP (0.18%), Blair William & Co. IL (0.15%), Inspire Advisors LLC (0.13%) and Mirae Asset Global Investments Co. Ltd. (0.07%). Insiders that own company stock include Alison Bauerlein, Brenton Taylor, Holdings A/S Novo, Ray Benjamin M Anderson and Raymond Huggenberger. View institutional ownership trends. How do I buy shares of Inogen? Shares of INGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:INGN) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithGold Set to EXPLODE!Gold Safe ExchangeThe Crypto 9-5 Escape PlanCrypto 101 MediaThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market InsidersUrgent Nvidia WarningAltimetryObama’s Forever Term [exposed]Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inogen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
